{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T06:53:33Z","timestamp":1779000813520,"version":"3.51.4"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is a difficult condition to treat. Cladribine selectively and transiently depletes B and T lymphocytes, leading to long\u2010lasting immune reconstitution. This report describes observations from 24\u00a0months of follow\u2010up after cladribine in NMOSD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective analysis of a case series including 12 seropositive patients with NMOSD. Patients were given cladribine by subcutaneous injections in a series of several 2\u2010day cycles of 20\u00a0mg administered at intervals of 4\u20136\u00a0weeks. Thus, the full treatment course delivered a cumulative bioavailable dose similar to that approved for treatment of multiple sclerosis. Annualized relapse rate (ARR), disability (Expanded Disability Status Scale [EDSS] score) and safety in the 24\u00a0months preceding and the 24\u00a0months following the initiation of cladribine treatment were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean ARR in the 24\u00a0months preceding cladribine treatment was 1.04 (95% confidence interval [CI] 0.67\u20131.62). The mean ARR in the 24\u00a0months following initiation of cladribine treatment was 0.21 (95% CI 0.08\u20130.56). The ratio in the rate of events post versus prior cladribine initiation was 0.20 (95% CI 0.07\u20130.59) and highly significant (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.0073). The EDSS score did not change over the follow\u2010up period (2.5\u00a0\u00b1\u00a01.7; mean\u00a0\u00b1\u00a0SD) compared to baseline (2.5\u00a0\u00b1\u00a01.5; mean\u00a0\u00b1\u00a0SD). No serious adverse events considered to be linked to cladribine were observed during follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Cladribine was safe in NMOSD patients over a 2\u2010year observation period. Cladribine treatment was associated with clinical stabilization, as evidenced by significantly decreased ARR and no progression of EDSS score.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.15012","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T18:27:59Z","timestamp":1625682479000},"page":"3167-3172","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cladribine suppresses disease activity in neuromyelitis optica spectrum disorder: a 2\u2010year follow\u2010up study"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7019-6681","authenticated-orcid":false,"given":"Konrad","family":"Rejdak","sequence":"first","affiliation":[{"name":"Department of Neurology Medical University of Lublin Lublin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Papu\u0107","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Lublin Lublin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0214-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577387"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000918"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000919"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.119"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420935019"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14124"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.10.006"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-305907"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000841"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16625-7"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000231"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.02.018"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313300"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317411"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.15012","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.15012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T21:56:41Z","timestamp":1693000601000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.15012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/ene.15012"],"URL":"https:\/\/doi.org\/10.1111\/ene.15012","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"2021-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}